Versartis, an US-based biotechnology company to treat growth hormone deficiency, has raised $21m in its series B round from a company including drugs group Amunix.
Alongside Amunix are venture capital (VC) firms New Leaf Venture Partners Advent Venture Partners and Index Ventures.
In June 2009, Versartis, raised $11m (with an option to add a further $5m) in its series A round from Amunix and Index Ventures.
Versartis was started as a joint venture between Amunix and Index to exploit Amunix’s recombinant PEGylation (rPEG) technology.